Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Expert Opinion: Management of Intraocular Inflammation and Vasculitis After Intravitreal Pegcetacoplan for Geographic Atrophy.

Ophthalmic surgery, lasers & imaging retina·2026

Same author

Plain language summary of publication of the 96-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema.

Therapeutic advances in ophthalmology·2026

Same author

Vision-related quality of life in non-neovascular age-related macular degeneration: a protocol for systematic review and meta-analysis.

Eye (London, England)·2026

Same author

Mid-Phase Hyperfluorescent Plaques as a biomarker of disease activity in Central Serous Chorioretinopathy: Clinical Course and Treatment Response - MICRoN report number Ten.

Retina (Philadelphia, Pa.)·2026

Same author

Inherited Retinal Disease Management in the United States: A Survey of Clinician Practice Patterns.

Retina (Philadelphia, Pa.)·2026

Same author

Real-World Insights on Switching Aflibercept Dosage for Enhanced Outcomes in Retinal Vein Occlusion (RISE-RVO): visual, anatomical and durability outcomes.

The British journal of ophthalmology·2026

Search research articles

Related Experiment Video

Updated: Jan 18, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Sozinibercept (Anti-VEGF-C/-D) Combined with Ranibizumab for Polypoidal Choroidal Vasculopathy: Phase IIb Predefined

Chui Ming Gemmy Cheung¹, Timothy L Jackson², Charles C Wykoff^3,4

¹Medical Retina Department, Singapore National Eye Center, Singapore Eye Research Institute, Singapore, Singapore.

Ophthalmology Science

|September 11, 2025

Summary

Sozinibercept combined with ranibizumab improved vision and reduced lesion activity in polypoidal choroidal vasculopathy (PCV) patients. This combination therapy demonstrated superior visual gains and anatomical improvements compared to ranibizumab alone.

Keywords:

Neovascular age-related macular degeneration Polypoidal choroidal vasculopathy Sozinibercept VEGF-C/-D

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Related Experiment Videos

Last Updated: Jan 18, 2026

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Oxygen-Induced Retinopathy Model for Ischemic Retinal Diseases in Rodents

Published on: September 16, 2020

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

Area of Science:

Ophthalmology
Medical Research
Pharmacology

Background:

Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration.
Current treatments like ranibizumab target VEGF-A, but PCV involves VEGF-C and VEGF-D pathways.
Sozinibercept is a novel inhibitor targeting VEGF-C and VEGF-D.

Purpose of the Study:

To evaluate the efficacy of sozinibercept in combination with ranibizumab for PCV treatment.
To assess the impact of VEGF-C and VEGF-D inhibition on visual acuity and anatomical outcomes in PCV.

Main Methods:

A randomized, double-masked, sham-controlled phase IIb trial subgroup analysis.
66 participants with treatment-naïve PCV received 6 intravitreal injections of ranibizumab 0.5 mg with either 0.5 mg or 2 mg sozinibercept, or sham.
Primary endpoint: change in best-corrected visual acuity (BCVA) at week 24; secondary endpoints: anatomical changes and safety.

Main Results:

The 2 mg sozinibercept combination group showed a significantly greater mean BCVA gain (+13.54 letters) compared to ranibizumab alone (+6.9 letters) at week 24 (P=0.0253).
More participants in the 2 mg sozinibercept group achieved ≥10 letter gains (77.3%) and ≥15 letter gains (40.9%) versus the ranibizumab group (47.4% and 31.6%).
Anatomical improvements were observed, with fewer participants in the 2 mg sozinibercept group experiencing subretinal fluid (19%) or intraretinal cysts (9.1%) compared to ranibizumab monotherapy (42.1% and 25%).

Conclusions:

Sozinibercept combination therapy, by inhibiting VEGF-C/-D, significantly improved visual and anatomical outcomes in PCV patients.
The 2 mg dose demonstrated a dose-dependent response, offering superior efficacy compared to ranibizumab monotherapy.
The safety profile of sozinibercept combination therapy was comparable to ranibizumab monotherapy.